Gemcitabine plus vinorelbine versus vinorelbine monotherapy in patients with metastatic breast cancer previously treated with anthracyclines and taxanes: final results of the phase III Spanish Breast Cancer Research Group (GEICAM) trial

Martín, Miguel; Ruı́z, Amparo; Muñoz, M.; Balil, A.; García-Mata, Jesús; Calvo, Lourdes; Carrasco, Eva; Mahillo, Esther; Casado, Antonio; García-Sáenz, José Ángel; Escudero, M.J.; Guillém, Vicente; Jara, Carlos; Ribelles, Nuria; Salas, Fernando Palacios; Soto, C.; Morales-Vásquez, Flavia; Rodrı́guez, César; Adrover, Encarna; Mel, J. R.

doi:10.1016/s1470-2045(07)70041-4

Cited by 170 publications

(112 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Response rates in the range of 21%-54% have been reported in phase II studies, depending on patient characteristics, dose and schedule of the two drugs, and type of previous chemotherapy administered [43][44][45]. A recently published phase III study, including metastatic breast cancer patients previously treated with anthracyclines and taxanes, at their first, second, or third line of treatment, demonstrated a significant advantage with the combination of the two drugs over vinorelbine alone in terms of the progression-free survival time (6 versus 4 months, respectively; p ϭ .0028), while the survival duration (15.9 versus 16.4 months; p ϭ .805) and response rate (36% versus 26%; p ϭ .093) were not different [46]. The incidence of hematological toxicity was significantly higher with the combination of the two drugs, while the incidence of nonhematological toxicity was low and manageable in both arms (level of evidence IbA).…”

Section: Combinations Without Anthracyclines and Taxanesmentioning

confidence: 99%

First-Line Chemotherapy for HER-2–Negative Metastatic Breast Cancer Patients Who Received Anthracyclines as Adjuvant Treatment

Morabito¹,

Piccirillo²,

Monaco³

et al. 2007

The Oncologist

View full text Add to dashboard Cite

After completing this course, the reader will be able to:1. Discuss the value of retreatment with anthracyclines for HER-2-negative metastatic breast cancer patients who received anthracyclines as adjuvant treatment.2. Discuss the role of liposomal anthracyclines, taxanes, and combinations without anthracyclines and taxanes, or innovative treatments, including target-based agents.3. Comment on the weakness and quality of available evidence.Access and take the CME test online and receive 1 AMA PRA Category 1 Credit ™ at CME.TheOncologist.com CME CME ABSTRACT

show abstract

Section: Combinations Without Anthracyclines and Taxanesmentioning

confidence: 99%

First-Line Chemotherapy for HER-2–Negative Metastatic Breast Cancer Patients Who Received Anthracyclines as Adjuvant Treatment

Morabito¹,

Piccirillo²,

Monaco³

et al. 2007

The Oncologist

View full text Add to dashboard Cite

show abstract

“…In addition, recent findings from studies of eribulin mesylate and nab-paclitaxel in patients who have received multiple lines of chemotherapy warrant attention. Various other agents-including liposomal doxorubicin, gemcitabine, and (with renewed interest) platinum analogs-have been studied for the treatment of mbc [19][20][21][22][23][24][25][26] . However, although those agents may also be considered potential alternatives for the treatment of mbc, they have not been engaged as the standard of care, and limited prospective data have been generated to enable a systematic review of their efficacy in that setting.…”

Section: Chemotherapy For Mbc: the Current State Of The Artmentioning

confidence: 99%

Advances in the Management of Metastatic Breast Cancer: Options Beyond First-Line Chemotherapy

Ayoub

Verma

2012

Current Oncology

View full text Add to dashboard Cite

This article provides an overview of recent advances in chemotherapy that may be used for the treatment of patients with locally advanced or metastatic breast cancer (mbc). Key phase ii and iii trial data for eribulin mesylate, ixabepilone, and nab-paclitaxel, published since 2006, are discussed on the basis of recency, depth, and quality. Eribulin mesylate is the first monotherapy to significantly increase overall survival in patients with pretreated mbc, but nab-paclitaxel offers a novel and safer mode of delivery in comparison with standard taxanes. By contrast, the use of ixabepilone will be limited for now, until the associated neurotoxicity can be better managed. Alongside a brief overview of the other major chemotherapies currently in use, we have aimed to provide a Canadian context for how these novel agents may be integrated into clinical practice.

show abstract

“…Anthracycline or taxane is considered first-line chemotherapy for MBC in patients who have not been exposed to these agents as adjuvants (1). However, the disease progression ultimately encountered is often attributed to primary or acquired resistance to these regimens (2).Traditional chemotherapeutic agents: gemcitabine (3,4), liposomal-doxorubicin (5,6), vinorelbine (3), platinum (7) (especially in the Triplo Negative Breast Cancer subgroup), have been used in the metastatic setting, with response rates between 10% and 35%.Therefore,there are few therapeutic possibilities that may be present in patients with anthacyclineresistant and taxane-resistant or refractory Metastatic Breast Cancer.Eribulin therapy is one of the few chemotherapy regimens shown to prolong OS of 2.5 months and the PFS of 1.5 months compared to other chemotherapy contributing to OS in women with heavily pretreated MBC. Its use may however be hampered by its cost,which is up to three times the cost of other standard drugs pretreated MBC.We report here on the safety and effectiveness of eribulin in women with MBC,placing particular attention to the costs of somministration of the drug,in relation to the results.…”

Section: Introductionmentioning

confidence: 99%

Sustainability of Eribulin Treatment for Patients with Metastatic Breast Cancer: is the Cost of the Drug Related to the Benefit Produced (Effectiveness and Safety)? a Single Center Experience

Günther

D’Aveni²,

Albanese³

2017

IAM

View full text Add to dashboard Cite

Objective: To report the clinical outcomes and health care costs of Metastatic Breast Cancer patients treated with Eribulin, in the Medical Oncology Unit of the Messina University. Method: We retrospectively analyzed the costs associated with eribulin treatment in 15 MBC patients from January 2014 to December 2016 at Messina University Hospital. The PFS , ORR , DCR and the average cost of patient therapy were calculated. Result:15 patients were included in this analysis. They had received a median of 4 lines of therapy previously (including adjuvant treatment) and had significant visceral involvement (median 3 organs). A median of 4 cycles of eribulin was delivered. There were partial responses in 20% patients , stable disease status in 14% , and progressive disease in 66% . The median progression-free survival was 15 weeks (3.5 months), ORR was 20%, DCR was 33% . The most frequent treatmentrelated adverse events were neutropenia (26%), and febrile neutropenia (20%). Therapy for these patients resulted in a cost of euros 158.244,76. Assessing the repayment by the pharmaceutical company equals to euros 20.238,37 for non -responders patients , there is a net cost of euros 138.006,39. Conclusion: Our results have shown that treatment with eribulin applied to patients pretreated in III / IV metastatic line and beyond, so the high percentage of nonresponders is determined because of the already expired general conditions at the beginning of treatment. Despite this ,eribulin was shown to be an effective and safe therapeutic option in heavily pretreated patients with MBC. The costs associated with eribulin therapy have shown that payment by result contributes to making the cost of therapy more sustainable by the National Health Service.

show abstract

Gemcitabine plus vinorelbine versus vinorelbine monotherapy in patients with metastatic breast cancer previously treated with anthracyclines and taxanes: final results of the phase III Spanish Breast Cancer Research Group (GEICAM) trial

Cited by 170 publications

References 25 publications

First-Line Chemotherapy for HER-2–Negative Metastatic Breast Cancer Patients Who Received Anthracyclines as Adjuvant Treatment

First-Line Chemotherapy for HER-2–Negative Metastatic Breast Cancer Patients Who Received Anthracyclines as Adjuvant Treatment

Advances in the Management of Metastatic Breast Cancer: Options Beyond First-Line Chemotherapy

Sustainability of Eribulin Treatment for Patients with Metastatic Breast Cancer: is the Cost of the Drug Related to the Benefit Produced (Effectiveness and Safety)? a Single Center Experience

Contact Info

Product

Resources

About